传承与发展丨长三角肺癌代表性论著阶段汇总

临床试验类

Chin Med J  Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer （2008）

J Thorac Oncol A multicenter, open-label, randomized phase II controlled study of rh-Endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (2015)

Radiother Oncol Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer (2015)

Ann Oncol  Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)  (2017)

J Thorac Oncol  Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung-A multicenter, open-label, randomized, phase III trial (2018)

J Clin Oncol  Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer (2018)

Lung Cancer  Factors associated with gene aberration test status and treatment decision in patients with unresectable stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506) (2018)

Am J Clin Oncol  Efficacy and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line chemotherapy: A single-arm, prospective, multicenter phase II study (RE-CHALLENGE, CTONG1304)   (2019)

J Thorac Dis Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial  (2019)

Radiother Oncol  HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (2020)

Cancer Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses (2020)

Lung Cancer A phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer-the FALUCA study (2020)

Clin Cancer Res Clonal architecture of EGFR mutation predicts the efficacy of EGFR-Tyrosine Kinase Inhitors in advanced NSCLC: a prospective multicenter study (NCT03059641) (2020)

Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)（2020）

转化研究类

J Thorac Oncol Analysis of the T descriptors and other prognosis factorsin pathologic stage I non-small cell lung cancer in China  (2010)

J Thorac Oncol  Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population (2010)

Clin Lung Cancer Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer (2011)

J Thorac Oncol A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer (2012)

Lung Cancer  The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines (2012)

Lung Cancer Regulation of SIRT2 levels for human non-small cell lung cancer therapy (2012)

Chest  Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer  (2013)

Clin Lung Cancer  Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer (2013)

Transl Lung Cancer Res   Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein (2013)

Br J Pharmacol  hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung caner  (2014)

Clin Cancer Res TERT polymorphism rs2736100-C is associated with EGFR mutation-positive non-small cell lung cancer (2015)

Transl Lung Cancer Res Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer (2015)

Transl Lung Cancer Res  Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice (2015)

EBioMedicine Multiplexed serum biomarkers for the detection of lung cancer  (2015)

Lung Cancer Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma (2016)

Lung Cancer Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma (2016)

Clin Cancer Res  Genome-wide DNA methylation analysis reveals GABBR2 as a novel epigenetic target for EGFR 19 deletion lung adenocarcinoma with induction erlotinib treatment  (2017)

P Natl Acad Sci USA  High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients (2017)

Transl Lung Cancer Res Correlation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma (2017)

Lung Cancer Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer (2017)

Clin Lung Cancer Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma (2017)

Clin Lung Cancer MET gene amplification and overexpression in Chinese non-small-cell lung cancer patients without EGFR mutations (2017)

Cancer Commun Epidermal growth factor receptor （EGFR） T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine inhibitor therapy：a prospective observational study (2018)

J Thorac Oncol  Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small-cell lung cancer (2018)

Oncogene FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer (2018)

J Cell Mol Med Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A single-center experience in China (2018)

Lung Cancer  Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer (2018)

Lung Cancer Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis (2018)

J Thorac Oncol Durable clinical response of lung adenocarcinoma harboring EGFR 19del/T790M/in trans-C797S to combination therapy of first-and third-generation EGFR TKIs (2019)

J Thorac Oncol EGFR and ERBB2 germline mutations in Chinese lung cancer patients and their roles in genetic susceptibility to cancer (2019)

Nat Commun  Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics (2019)

J Thorac Oncol  The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients (2019)

EBioMedicine Value of folate receptor-positive circulating tumor cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumor invasiveness (2019)

Transl Lung Cancer Res 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis (2019)

Transl Lung Cancer Res Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment (2019)

Transl Lung Cancer Res Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma (2019)

Lung Cancer Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients (2019)

Lung Cancer  Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer (2019)

Clin Lung Cancer Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: A multicenter retrospective study (2020)

Lung Cancer  Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer (2020)

Transl Lung Cancer Res  Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort (2020)

Transl Lung Cancer Res Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study (2020)

Transl Lung Cancer Res Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis (2020)

Cancer Sci Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study (2020)

Clin Cancer Res Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC (2020)

Clin Chem Simultaneous detection of gene fusions and base mutations in cancer tissue biopsies by sequencing dual nucleic acid templates in unified reaction (2020)

Oncogene Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma (2020)

Eur J Nucl Med Mol Imag The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients (2020)

Mol Ther Methods Clin Dev  Evaluating the potential of T cell receptor repertoires in predicting the prognosis of resectable non-small cell lung cancers (2020)

Cancer Lett Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer (2020)

Transl Lung Cancer Res The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment （2021）

Cancer Commun High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion （2021）

Cell Death Dis Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis（2021）

Transl Lung Cancer Res Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort（2021）

Transl Lung Cancer Res A large real-world chort study of examined lymph node standards or adequate nodal staging in early non-small cell lung cancer（2021）

Meta分析类

J Thorac Oncol Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis (2009)

Lung Cancer  A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: Evidence from 15,857 subjects (2009)

J Thorac Oncol  ERCC2/XPD Lys 751 Gln and Asp 312 Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies (2010)

Lung Cancer CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians (2010)

J Exp Clin Cancer Res  CYP1A1 MspI and exon 7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review (2011)

Eur J Cancer  Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis (2011)

J Thorac Oncol  Alpha 1-Antitrypsin deficiency carriers, serum Alpha 1-antitrypsin concentration, and non-small-cell lung cancer survival (2011)

J Exp Clin Cancer Res  XRCC3 Thr 241 Met gene polymorphisms and lung cancer risk: a meta-analysis (2013)

J Thorac Oncol   Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph Node staging in non-small cell lung cancer: A bivariate systematic review and meta-analysis (2013)

Transl Lung Cancer Res  Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review (2013)

Transl Lung Cancer Res  Association of the metformin with the risk of lung cancer: a meta analysis (2013)

Transl Lung Cancer Res  The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated nonsmall

cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis (2015)

Transl Lung Cancer Res  Prognostic value of Twist in lung cancer: systematic review and meta-analysis (2015)

Transl Lung Cancer Res  Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis (2015)

Transl Lung Cancer Res PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis (2015)

Transl Lung Cancer Res  Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis (2015)

Transl Lung Cancer Res  A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients (2015)

Transl Lung Cancer Res  CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis (2015)

Lung Cancer  Can EGFR mutations in plasma or serum be predictive markersof non-small-cell lung cancer? A meta-analysis (2015)

Transl Lung Cance Res  Prognostic value of wingless-type proteins in non-small cell lung cancer patients: a meta-analysis (2016)

Transl Lung Cancer Res  Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis (2016)

Transl Lung Cancer Res  Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta analysis (2016)

Clin Lung Cancer  Meta-analysis of first-line pemetrexed plus platinum treatment in compared to other platinum-based doublet regimens in elderly East Asian patients with advanced nonsquamous non-small-cell lung cancer (2016)

Transl Lung Cancer Res Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis (2017)

Transl Lung Cancer Res  Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis (2017)

Transl Lung Cancer Res  Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: a systematic review and meta-analysis (2017)

Transl Lung Cancer Res  Efficacy of rapid on-site evaluation for diagnosing pulmonary lesions and mediastinal lymph nodes: a systematic review and meta-analysis (2019)

Transl Lung Cancer Res  Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis (2019)

Transl Lung Cancer Res  The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials (2019)

Transl Lung Cancer Res  The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients (2019)

Transl Lung Cancer Res   Efficacy of rapid on-site evaluation for diagnosing pulmonary lesions and mediastinal lymph nodes: a systematic review and meta-analysis (2020)

Transl Lung Cancer Res Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis (2020)

Transl Lung Cancer Res  Comparison of autofluorescence and white-light bronchoscopies performed with the Evis Lucera Spectrum for the detection of bronchial cancers: a meta-analysis (2020)

基础研究类

J Biol Chem   Endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest and apoptosis through down-regulation of the phosphhatidylinositide 3-kinase/Akt/HDM2 pathway （2015）

Cancer Lett PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer (2015)

J Cell Mol Med  17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway (2015)

Mol Cancer  PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway (2017)

J Cell Mol Med NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma (2017)

J Cell Mol Med Long non-coding RNA 00312 regulated by HOXA5 inhibits tumor proliferation and promotes apoptosis in non-small cell lung cancer (2017)

J Exp Clin Cancer Res  FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells (2017)

J Cell Mol Med Overexpression of geranylgeranyl diphosphate synthase contributes to tumor metastasis and correlates with poor prognosis of lung adenocarcinoma (2018)

J Cell Mol Med TEAD4 exerts pro-metastatic effects and is negatively regulated by miR6839-3p in lung adenocarcinoma progression (2018)

J Exp Clin Cancer Res  SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4 (2018)

EBioMedicine Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer  (2018)

Cancer Lett The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer  (2018)

Oncogene Cell type-dependent function of LATS1/2 in cancer cell growth (2018)

Cancer Commun  Xenograft tumors derived from malignant pleural effusion of the patients with non‑small‑cell lung cancer as models to explore drug resistance  (2018)

Oncogene WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression (2019)

Oncogenesis Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer (2019)

Nat Commun Fas signaling-mediated TH9 cell differentiation favors bowel inflammation and antitumor functions (2019)

Cell Res s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide (2020)

Cancer Sci Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR‐497‐5p/mTOR (2020)

纳米工程类

Chem Commun Exterior modification of a DNA tetrahedron (2010)

ACS Nano DNA polyhedra with T-linkage (2012)

Angew Chem Int Ed Controlling the chirality of DNA Nanocages (2012)

J Am Chem Soc Artificial, parallel, left-handed DNA helices (2012)

Angew Chem Int Ed Directed self-assembly of DNA tiles into complex Nanocages (2014)

Nat Commun Construction of RNA nanocages by re-engineering the packaging RNA of Phi29 bacteriophage (2014)

Nat Commun De novo design of anRNA tile that self-assembles into a homo-octameric nanoprism (2015)

J Control Release Self-assembled triangular DNA nanoparticles are anefficient system for gene delivery (2016)

J Am Chem Soc Retrosynthetic analysis-guided breaking tile symmetry for the assembly of complex DNA Nanostructures  (2016)

Chem Sci Protecting microRNAs from RNase degradation with stericDNA nanostructures  (2018)

Chem Sci Capturing intracellular oncogenic microRNAs with self-assembled DNA nanostructures for microRNA based cancer therapy (2018)

Nat Commun Invivo production of RNA nanostructures via programmed folding of single-strandedRNAs  (2018)

Acs Appl Mater Inter Isothermal self-assembly of spermidine/DNA Nanostructure complex as a functional platform for cancer therapy (2018)

ChemBioChem Targeted delivery of Rab26 siRNA with precisely tailored DNA prism for lung cancer therapy (2019)

Small Assembling defined DNA Nanostructure with Nitrogen-enriched carbon dots for theranostic cancer applications (2020)

参与的国内国际临床试验

Lancet  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial   Mei-lin Liao (2008)

J Clin Oncol  Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer  Mei-lin Liao (2009)

J Clin Oncol Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial  Mei-lin Liao (2010)

J Thorac Oncol  Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)  Mei-lin Liao (2011)

J Thorac Oncol  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer  Mei-lin Liao (2011)

Lancet Oncol  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study  Shun Lu, Yi-ping Zhang (2011)

Lancet Oncol Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial  Shun Lu，Sheng-lin Ma (2011)

Lung Cancer Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer （NSCLC）：Preliminary results of a phase II study  Sheng-lin Ma （2011）

J Clin Oncol Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer Mei-lin Liao (2012)

Lancet Oncol Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Mei-lin Liao (2013)

Ann Oncol  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)  Shun Lu (2013)

BMC Cancer A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung  Yong Song (2013)

Lancet Oncol  Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial  Yong Song, Yi-ping Zhang (2013)

Lancet Oncol Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Mei-lin Liao (2014)

Lancet Oncol  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Shun Lu (2014)

Lung Cancer Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer  Shun Lu (2014)

J Clin Oncol BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer  Shun Lu (2014)

Ann Oncol Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous non-small-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial  Yong Song (2014)

Lung Cancer A single-arm，multicenter，safety-monitoring，phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC) Yi-ping Zhang (2014)

Clin Cancer Res  Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated Erlotinib and chemotherapy Mei-lin Liao (2015)

Eur J Cancer Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cance  Mei-lin Liao (2015)

Jpn J Clin Oncol  Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study  Mei-lin Liao (2015)

J Thorac Oncol  Symptom and quality of life improvement in LUX-Lung 6: An open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small cell lung cancer  Shun Lu (2015)

J Thorac Oncol  Final overall survival results from a phase III, randomized,

placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)  Shun Lu，Sheng-lin Ma (2015)

Ann Oncol  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial  Shun Lu (2015)

Ann Oncol Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Shun Lu (2015)

Ann Oncol First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study  Shun Lu (2015)

Lancet Oncol Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials  Shun Lu (2015)

Lancet Oncol  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial  Shun Lu (2015)

Plos One  The efficacy and safety of Icotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy: A single-arm, multi-center, prospective study Yong Song (2015)

Medicine Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung（C-TONG 0807）：an open-label，single arm，multicenter phase II study Yi-ping Zhang (2015)

Lancet Oncol  Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial  Mei-lin Liao (2016)

Asia-Pacific J Clin Oncol  An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer  Shun Lu (2016)

Lancet Respir Med  Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicenter, phase 3, open-label, parallel, randomised controlled trial  Shun Lu，Yong Song (2016)

Br J Cancer  EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6  Shun Lu (2016)

Lancet Oncol Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung7): a phase 2B, open-label, randomized controlled trial  Shun Lu (2016)

Ann  Oncol  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial  Shun Lu (2016)

Ann Oncol  Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials  Shun Lu (2016)

J Thorac Oncol  Results of PROFILE 1029, a phase III comparison of first-line Crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer  Shun Lu (2017)

Lung Cancer Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study Shun Lu (2017)

Ann Oncol  First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study  Yong Song (2017)

Lung Cancer  EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study  Yi-ping Zhang (2017)

J Thorac Oncol  The unique spatial-temporal treatment failure patterns of adjuvant Gefitinib Therapy: A Post Hoc  analysis of the ADJUVANT trial (CTONG 1104)  Mei-lin Liao (2018)

J Clin Oncol  Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer  Shun Lu (2018)

JAMA Oncol  Association of ERBB mutations with clinical outcomes of afatinib-or erlotinib-treated patients with lung squamous cell carcinoma secondary analysis of the LUX-Lung 8 randomized clinical trial  Shun Lu (2018)

J Thorac Oncol Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-Positive advanced non-small cell lung cancer Shun Lu (2018)

Lung Cancer  Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies  Shun Lu (2018)

Onco Targets Ther Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial  Shun Lu (2018)

Cancer  Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study  Yong Song (2018)

Lancet Respir Med  Detection of EGFR mutations in plasma circulating tumor DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial Yong Song (2018)

Eur J Cancer  A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)  Yong Song (2018)

Br J Cancer  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II  trial (ALTER0302)  Yi-ping Zhang (2018)

Invest New Drugs   Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer  Yi-ping Zhang (2018)

Lung Cancer  First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials Shun Lu (2019)

J Thorac Oncol  Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial  Shun Lu, Yi-ping Zhang (2019)

Lancet Respir Med Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  Yi-ping Zhang (2019)

Lancet Respir Med  Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial  Yong Song, Yi-ping Zhang (2019)

N Engl J Med Osimertinib in resected EGFR-mutated non-small-cell lung cancer   Shun Lu (2020)

Lancet Respir Med Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial  Shun Lu, Yi-ping Zhang (2020)

J Thorac Oncol Safety, Efficacy and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase I trial Shun Lu (2020)

J Thorac Oncol Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage non-small cell lung cancer Shun Lu (2020)

Transl Lung Cancer Res  Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer  Shun Lu, Yong Song, Sheng-lin Ma，Yi-ping Zhang (2020)

J Thorac Oncol   Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology program by Innov ENT anti-PD-1-11)  Yong Song (2020)

Clin Cancer Res  Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases: the APOLLO study  Yong Song (2020)

Int J Radiat Oncol Biol Phys Erlotinib versus Etoposide/Cisplatin with radiation therapy in unresectable stage III Epidermal Growth Factor Receptor mutation-positive non-small cell lung cancer：A multicenter，randomized，open-label，phase 2 trial Sheng-lin Ma (2020)

J Clin Oncol  Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-Based chemotherapy: A multicenter, open-label, single-arm, phase II study  Yi-ping Zhang (2020)

Ann Oncol Comparing nanoparticle polymeric micellar paclitaxel and solvent-basedpaclitaxel asfirst-line treatment of advanced non-small-cell lung cancer anopen-label, randomized, multicenter,phase III trial   Yi-ping Zhang (2020)

Lancet Oncol  Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study  Yi-ping Zhang (2020)

Lancet Respir Med Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotheray-naive patients with advanced non-squamous non-small-cell lung cancer (CameL) : a randomised, open-label, multicentre, phase 3 trial  Yi-ping Zhang (2020)

Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)  Yi-ping Zhang (2020)

推荐阅读

肺癌系列文章汇总 (2021年1月)肺癌，临床试验招募汇总

加微信号：251170937，方便免费咨询和寻找最合适的免费治疗项目

整理者